Q-omics provides the consensus-scored IL17RA profile across patient tissues and cancer cell-line models. IL17RA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IL17RA is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, IL17RA RNA expression shows 19,528 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where IL17RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17RA survival associations across molecular data types. IL17RA RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17RA RNA expression–survival associations across cancer types. High IL17RA expression shows unfavorable associations in KICH, ACC, UVM and LGG, but favorable associations in SKCM and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for IL17RA RNA expression.
This table summarizes IL17RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL17RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17RA shows lower tumor expression in LUAD and higher tumor expression in HNSC, KIRC, KIRP, STAD and LIHC. The HNSC box plot shows higher IL17RA RNA expression in tumor versus normal tissue (log2 FC = +0.973, t-test p < 0.001).
This table shows molecular features associated with IL17RA in patient tissues and cancer cell lines. In patient samples, IL17RA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
